Q2 2020 Earnings

Revenue

$48M-10.8% YoY

Gross Profit

$28M57.3% margin

Operating Income

-$11M-23.3% margin

Net Income

-$12M-25.5% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

-2.6%

Operating Cash Flow

$21M

Free Cash Flow

$18M

Stock-Based Comp.

$6M

Total Assets

$465M

Total Liabilities

$274M

Stockholders' Equity

$191M

Cash & Equivalents

$28M

Metric	Current	Year Ago	Change
Revenue	$48M	$54M	-10.8%
Gross Profit	$28M	$39M	-28.3%
Operating Income	-$11M	$9M	-221.7%
Net Income	-$12M	$6M	-290.4%

Sales Of Generic Pharmaceutical Products

$33M65%

Sales Of Branded Pharmaceutical Products

$11M21%

Sales Of Contract Manufactured Products

$6M11%

Product Development Services

$885,0002%

Royalties From Licensing Agreements

$491,0001%

Other Revenues

$161,0000%

$46M95%

$2M5%